Mallinckrodt has permanently suspended a Phase IIb clinical trial of its Acthar Gel (repository corticotropin injection) in patients with amyotrophic lateral sclerosis (ALS).

The study was designed to compare the safety and efficacy of the injection with placebo over 36 weeks in subjects aged 18 to 75.

Acthar Gel’s efficacy was measured as functional decline, including change in the ALS Functional Rating Scale-Revised from baseline, at 36 weeks following treatment.

The decision to halt the trial comes after its independent Data and Safety Monitoring Board (DSMB) highlighted higher pneumonia rate in participants on Acthar Gel versus placebo.

In addition, the DSMB noted additional adverse events and no clear efficacy signal for the patient population.

The company will immediately stop patient enrolment into the trial and existing participants will be tapered off the injection drug prior to discontinuation of use.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mallinckrodt executive vice-president and chief scientific officer Steven Romano said: “Mallinckrodt’s primary focus is on the safety of patients and, while ALS patients are among those most in need of new therapies and treatment options, we believe this is the right decision.

“Though the probability of success for the ALS population was acknowledged as being low, this study was initiated based on compelling analyses carried out following the completion of a small pilot study and we were hopeful it would have translated into a benefit for this group of patients in great need of effective therapies.”

The company added that the suspension of this Phase IIb trial will not impact Acthar Gel’s other studies.

Mallinckrodt invested more than $500m in Acthar Gel, which currently holds US regulatory approval in 19 indications, including rheumatoid arthritis and infantile spasms.